| Name | Title | Contact Details |
|---|
Hospice of Central Michigan is a Mount Pleasant, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NovaSom is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2013, Palm Medical Centers is a provider of value-based, capitated primary care services with a focus on high-quality clinical outcomes, cost-effective care, and a patient-centric experience. Operating a network of 19 medical centers across five counties in Florida, PMC serves more than 34,000 Medicare Advantage and managed Medicaid patients. Partnering with numerous managed care organizations, Palm Medical Centers offers comprehensive and integrated medical care to plan members with a focus on quality. In addition to primary care services, the company coordinates cardiology, dentistry, optometry, pediatrics, podiatry, psychiatry and other specialist services. Palm Medical Centers continues to seek partnership opportunities with high quality providers in existing and new markets.
Sonrava Health is the parent organization of a national family of health and wellness companies, united by a singular dedication to delivering high-quality, convenient and affordable care through innovative provider models, health coverage and product offerings. Building on a proven platform of success, the brand will continue to expand access to dental and vision care with a mission of advancing whole-person health for patients from all backgrounds. A geographically diverse, multi-specialty organization with a unique mix of providers and payors, Sonrava Health is comprised of several companies – including Western Dental & Orthodontics, Western Dental Kids, Brident Dental & Orthodontics, Brident Dental Kids, LooksBrite Eye Centers, EyeMax Vision Plan, MIB Insurance Plans, Vital Smiles, MID-Atlantic Dental Partners, DentalWorks, and Perfect Teeth – all united in our commitment to quality, value and innovation in care.
Voyager Therapeutics is developing life-changing gene therapies from discovery, preclinical and clinical development, through to commercialization. We focus on people living with severe neurological diseases that lack safe and effective treatment options, particularly in the areas of Parkinson`s disease, monogenic forms of amyotrophic lateral sclerosis (ALS), Friedreich`s ataxia, Huntington`s disease, Alzheimer`s Disease and other tau-related neurodegenerative diseases, and severe, chronic pain. We are also committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, dosing techniques, as well as process development and production. Our management team and founders represent some of the most esteemed scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference, neuroscience preclinical and clinical development, and manufacturing. We have broad strategic collaborations with Genzyme, a Sanofi company, AbbVie and the University of Massachusetts Medical School (UMMS). We have also entered into license and other agreements with UMMS, the University of California San Francisco and Stanford University to access relevant technology and data.